However, since G12D is the most common alteration of KRAS in PDAC these tumors are not amenable to treatment with G12C-specific agents, in contrast to many lung cancers and the 2% subset of pancreatic cancer patients carrying a G12C mutation that has been successfully hit. This evidence concerns the gene KRAS and lung carcinoma.